Navigation Links
Study shows PFO closure may be superior to medical therapy in preventing stroke
Date:10/25/2012

HOUSTON (Oct. 25, 2012) Results of a large-scale, randomized clinical trial called RESPECT revealed that patent foramen ovale (PFO) closure may be superior to medical therapy in preventing recurrent stroke, according to a presentation of findings today at the Transcatheter Cardiovascular Therapeutics (TCT) conference in Miami.

"In contrast to a previously reported randomized trial for the treatment of cryptogenic stroke, the RESPECT trial enrolled only patients with documented cryptogenic embolic strokes and excluded patients with other potential causes of stroke and/or TIA. The period of follow-up approached nine years and was not restricted to only events within the initial two years of follow-up," said Richard Smalling, M.D., Ph.D., James D. Wood Distinguished Chair in Cardiovascular Medicine at The University of Texas Health Science Center at Houston (UTHealth), who served on the steering committee and as a principal investigator of the trial.

"As a result, the trial enrolled patients at high-risk for recurrent events and followed them for a long period of time, enabling the detection of relatively infrequent recurrent stroke," said Smalling, who is director of interventional cardiovascular medicine at the Memorial Hermann Heart and Vascular Institute. "The totality of evidence in the RESPECT trial clearly demonstrates the superiority of device closure using the Amplatzer PFO Occluder in patients with the above entry criteria compared to standard medical therapy."

According to the National Institutes of Health, a PFO is a hole between the left and right atria (upper chambers) of the heart that fails to close naturally soon after a baby is born. In about one in four people, the hole never closes. The condition is usually not treated unless there are other heart problems or the person has a stroke caused by a blood clot. PFO has been a suspected cause of cryptogenic stroke, meaning a stroke without any identifiable cause usually occurring in people under the age of 55.

The trial enrolled 980 patients from 69 sites over eight years, yielding 2,300 patient-years of data. Medical group regimens were antiplatelet medications or warfarin. All primary endpoint events were recurrent ischemic strokes. As treated, five of the patients in the closure group had a stroke compared to 16 in the medically treated group.

"These patients with cryptogenic stroke are typically young and in the height of the productive period of their lives. Preventing a recurrent, potentially devastating, stroke by implanting a small device with very little risk is a huge potential benefit," Smalling said.


'/>"/>
Contact: Deborah Mann Lake
deborah.m.lake@uth.tmc.edu
713-500-3030
University of Texas Health Science Center at Houston
Source:Eurekalert

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Study reveals how cancer drug causes diabetic-like state
3. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
6. No Added Cancer Risk From Hip Replacement Materials: Study
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Early Study Finds Some Promise for Lung Cancer Vaccine
9. Narcissists Often Ace Job Interviews, Study Finds
10. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
11. Soy may alleviate hot flashes in menopause, large-scale study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2019)... N.Y. (PRWEB) , ... November 15, 2019 , ... ... of over 100 employers in Newsday’s Top Long Island Workplaces for 2019. The ... , During the selection process, Newsday worked in partnership with Energage to ...
(Date:11/14/2019)... (PRWEB) , ... November 14, 2019 , ... ... treatments for cancers and other serious diseases, announced it will have 5 poster ... at the upcoming 24th Annual Society for Neuro-Oncology SNO Meeting in Phoenix, beginning ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... individuals/organizations who have truly impacted those diagnosed with infertility. This year, Academy of ... Award for Achievement, presented at the Night of Hope Gala in New York ...
(Date:11/12/2019)... (PRWEB) , ... November 12, 2019 , ... ... most complete business management solution for physical therapy and rehabilitation operators throughout the ... engagement technology with customers in 102 countries, today announces a joint venture to ...
(Date:11/11/2019)... ... November 11, 2019 , ... Thermal Product Solutions, a ... Gruenberg Depyrogenation Sterilizers to the Pharmaceutical Industry. The units will be used ... 280°C with work chamber dimensions of 36” W x 36” D x 53” ...
Breaking Medicine News(10 mins):
(Date:11/16/2019)... , ... November 15, 2019 , ... ... living with memory impairment, has announced the Best Memory Care Facilities in Columbus, ... experts, facility features and amenities. , According to the Alzheimer’s Association ...
(Date:11/16/2019)... ... November 15, 2019 , ... October 29 article ... any time when more than usual is being consumed – is best done near ... doing so, the sugars and acids found in candy are more likely to be ...
(Date:11/15/2019)... ... , ... JustCBD looks forward to working with Hope For The ... by the military families aboard Marine Corps Base Camp Lejeune, North Carolina. These families ... the past 13 years, Hope For The Warriors has been dedicated to serving those ...
Breaking Medicine Technology: